Aurobindo Pharma Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Aurobindo Pharma Ltd filed with BSE on 13 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Aurobindo Pharma reported Q1 FY27 consolidated revenue up 16% year-on-year to Rs 9,150 crores, with operating EBITDA at Rs 1,924 crores and a margin of 21%, driven by growth across formulations, API, US, Europe and growth markets. Management highlighted the completion of the Lannett acquisition, doubling of production at the China OSD facility, and progress in the biosimilars and TheraNym biologics contract manufacturing pipeline. The company reiterated its FY27 guidance of double-digit revenue growth, EBITDA margins above 21%, and absolute EBITDA exceeding Rs 8,000 crores.
Numbers mentioned
Consolidated revenue: Rs. 9,150 crores (Q1 FY27)
p. 3
“Our consolidated revenues increased by 16% year-on-year to Rs. 9,150 crores driven by broad-based performance across our business area.”
S. Subramanian, page 3 of the filed PDF · View the filing
Operating EBITDA: Rs. 1,924 crores (Q1 FY27)
p. 3
“Operating EBITDA, exploring one-time impact of Rs. 43 crores towards a loss on derecognition of leased residuals, stood at Rs. 1,924 crores with a margin of 21%.”
S. Subramanian, page 3 of the filed PDF · View the filing
Formulation business revenue: Rs. 8,101 crores (Q1 FY27)
p. 3
“Our formulation business remained a primary growth driver, growing 17% year-on-year to Rs. 8,101 crores and contributing approximately 89% of the consolidated revenues, supported by growth across all key markets.”
S. Subramanian, page 3 of the filed PDF · View the filing
API business revenue: Rs. 1,049 crores (Q1 FY27)
p. 3
“API business clocked revenue Rs. 1,049 crores accounting for 11% of the overall revenues supported by our backward integration strategy.”
S. Subramanian, page 3 of the filed PDF · View the filing
US revenue: Rs. 3,770 crores or $399 million (Q1 FY27)
p. 3
“U.S. revenues grew by 8.1% year-on-year to Rs. 3,770 crores or $399 million reflecting the resilience of our base business.”
S. Subramanian, page 3 of the filed PDF · View the filing
Europe revenue: €267 million (Q1 FY27)
p. 3
“Our European business continued its strong trajectory with revenues reaching €267 million, delivering 11% year-on-year growth in constant currency terms.”
S. Subramanian, page 3 of the filed PDF · View the filing
Growth markets revenue: Rs. 1,063 crores or $113 million (Q1 FY27)
p. 3
“Growth markets revenues increased by 38% year-on-year to Rs. 1,063 crores or $113 million, supported by strong underlying performance across key markets.”
S. Subramanian, page 3 of the filed PDF · View the filing
ARV formulation revenue: $35 million (Q1 FY27)
p. 3
“ARV formulation remained stable at $35 million for the quarter, driven by stable volume.”
S. Subramanian, page 3 of the filed PDF · View the filing
Gross margin: 60.4% (Q1 FY27)
p. 4
“Gross margin remained resilient at 60.4% compared to 58.8% of Q1 FY26, benefiting from an improved business mix and operating efficiency.”
S. Subramanian, page 4 of the filed PDF · View the filing
Net CapEx: $78 million (Q1 FY27)
p. 4
“Net CapEx for the quarter stood at $78 million.”
S. Subramanian, page 4 of the filed PDF · View the filing
R&D expenses: around Rs. 350 crores (Q1 FY27)
p. 4
“R&D expenses for the quarter is around Rs. 350 crores, amounting to 4% of the revenues.”
S. Subramanian, page 4 of the filed PDF · View the filing
Net cash position: $42 million (Q1 FY27)
p. 4
“Our balance sheet continues to remain strong with a strong net cash position of $42 million after payment of $85 million towards buyback and $247 million for Lannett acquisition, reinforcing our strong financial resilience and focus on various accretive growth opportunities while maintaining a disciplined capital structure.”
S. Subramanian, page 4 of the filed PDF · View the filing
Average finance cost: 4.8% (Q1 FY27)
p. 4
“Our average finance cost declined to 4.8% from 5% in the previous quarter, reflecting prudent treasury management.”
S. Subramanian, page 4 of the filed PDF · View the filing
Net effective tax rate: 31.9% (Q1 FY27)
p. 4
“Our net effective tax rate is 31.9% on account of not taking the tax credit on loss-making subsidiaries.”
S. Subramanian, page 4 of the filed PDF · View the filing
Profit after tax: Rs. 1,032 crores (Q1 FY27)
p. 4
“Profit after tax stood at Rs. 1,032 crores, reflecting a healthy operating leverage and efficient capital management.”
S. Subramanian, page 4 of the filed PDF · View the filing
A1 Biochem turnover: around 100 crores
p. 11
“A1 Biochem as on date is having a turnover of around 100 crores, right?”
S. Subramanian, page 11 of the filed PDF · View the filing
Lannett facility utilization: 40 percent
p. 9
“So, we have about 40 percent utilization and then we plan to take it to a decent level.”
Swami Iyer, page 9 of the filed PDF · View the filing
China OSD plant capacity: more than 2 billion tablets
p. 11
“So, the China plant, we are having a capacity of more than 2 billion tablets.”
S. Subramanian, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — double-digit revenue growth · FY27
stated firmly by S. Subramanian
p. 4
“We continue to reiterate our FY27 guidance to double-digit revenue growth, with EBITDA margins north of 21% and absolute EBITDA in excess of 8000, with potential upside driven by positive outperformance in our high-value strategic business areas.”
S. Subramanian, page 4 of the filed PDF · View the filing
EBITDA margin — north of 21% · FY27
stated firmly by S. Subramanian
p. 4
“We continue to reiterate our FY27 guidance to double-digit revenue growth, with EBITDA margins north of 21% and absolute EBITDA in excess of 8000, with potential upside driven by positive outperformance in our high-value strategic business areas.”
S. Subramanian, page 4 of the filed PDF · View the filing
Tax rate — 28-29% · by year-end
stated conditionally by S. Subramanian
p. 4
“However, we expect the tax rate to normalise around 28-29% by year-end.”
S. Subramanian, page 4 of the filed PDF · View the filing
R&D expenditure — Rs. 1,450 to 1,500 crores · FY27
stated firmly by S. Subramanian
p. 15
“And this year it will be somewhere around Rs. 1,450 to 1,500, that's the maximum we have seen.”
S. Subramanian, page 15 of the filed PDF · View the filing
US biosimilar filings — at least three products in the US · by 2030
stated as an aspiration by Satakarni Makkapati
p. 9
“which underpins the at least three products in the US aspiration that I laid out in some of the previous earnings calls by 2030”
Satakarni Makkapati, page 9 of the filed PDF · View the filing
EU/UK/Canada biosimilar approvals — seven to eight products · by 28-29
stated as an aspiration by Satakarni Makkapati
p. 10
“my guidance for a broader seven to eight products in EU, UK, Canada by 28-29 is on track with four approvals already received.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
Omalizumab EU filing — filing with European Medicines Agency · Q3
stated firmly by Satakarni Makkapati
p. 9
“The filing is on track for Q3 with European Medicines Agency.”
Satakarni Makkapati, page 9 of the filed PDF · View the filing
TheraNym unit one qualification — qualification activities of the facility and equipment · by November 2026
stated firmly by Satakarni Makkapati
p. 10
“And we remain on track to begin qualification activities of the facility and the equipment by November 2026.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
TheraNym unit one revenue — steady revenue stream · from 2028
stated conditionally by Satakarni Makkapati
p. 10
“So, in the nutshell, you can expect a steady revenue stream from 2028, depending on the stockpiling efforts of the customer.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
TheraNym unit two commissioning — commissioned by end 2029 · end 2029
stated conditionally by Satakarni Makkapati
p. 10
“That would be commissioned by end 2029, provided I get all the statutory clearances and environmental clearance to begin construction this October.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
TheraNym unit two revenue start — revenues from 2031 · 2031
stated conditionally by Satakarni Makkapati
p. 10
“which means 2031 will be when the unit two will start to generate the revenues.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
Contract manufacturing revenue (Unit 1 + Unit 2) — US$150 to $200 million · from 2032 onwards
stated as an aspiration by Satakarni Makkapati
p. 19
“But in all, I expect it to be a $150-200 million revenue guidance from 2032 onwards between both Unit 1 and Unit 2, if that helps you.”
Satakarni Makkapati, page 19 of the filed PDF · View the filing
Contract manufacturing EBITDA margin — 35 to 50%
stated as an aspiration by Satakarni Makkapati
p. 19
“And the margins in this business typically are around, the EBITDA margins will be around 35 to 50%.”
Satakarni Makkapati, page 19 of the filed PDF · View the filing
Europe revenue growth — double digit growth · FY27
stated firmly by V. Murlidharan
p. 13
“And FY27, definitely we are expecting to close with a double digit growth over the previous year.”
V. Murlidharan, page 13 of the filed PDF · View the filing
China plant capacity utilization — beyond 2 billion tablets · by end of the year or mid of next year
stated conditionally by S. Subramanian
p. 11
“So, our objective is to go beyond 2 billion, probably by end of the year or mid of the next year.”
S. Subramanian, page 11 of the filed PDF · View the filing
Eugia revenue — around 500 million plus · this year
stated firmly by Yugandhar Puvvala
p. 13
“And we will clock around 500 million plus revenue for the year.”
Yugandhar Puvvala, page 13 of the filed PDF · View the filing
Eugia revenue growth — single digit growth · this year
stated firmly by Yugandhar Puvvala
p. 14
“So it is a, this year we expect that the single digit growth will continue.”
Yugandhar Puvvala, page 14 of the filed PDF · View the filing
EBITDA quarterly run rate — 2200 crores a quarter · next quarter
stated conditionally by S. Subramanian
p. 20
“We should be looking at it. But let us wait how the geopolitical situation in the Middle East is getting over.”
S. Subramanian, page 20 of the filed PDF · View the filing
A1 Biochem revenue growth — three to five X · over three to five years
stated as an aspiration by S. Subramanian
p. 12
“And he has a very big vision of taking it to at least three to five X in over a period of three to five years.”
S. Subramanian, page 12 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said growth was broad-based across countries with no single standout market.
Answered by S. Subramanian
Asked by Tausif Shaikh: What is driving growth markets performance and are specific countries responsible?
p. 6
“All the growth market countries are driving growth in line with the normal. There is no specific country which is growing extraordinarily like that.”
S. Subramanian, page 6 of the filed PDF · View the filing
Management said the launch was not delayed but required inventory build-up ahead of launch.
Answered by Swami Iyer
Asked by Tausif Shaikh: When will Advair launch and why the delay?
p. 6
“So, it's not delayed. It's just that the product had to be ready.”
Swami Iyer, page 6 of the filed PDF · View the filing
Management explained growth is constrained by a fixed national quota system for controlled substances.
Answered by Swami Iyer
Asked by Damayanti Kerai: Is there headroom to grow controlled substance products at Lannett?
p. 7
“So, Lannett happens to be one of the suppliers. So, we should not expect any sudden jump unless somebody defaults.”
Swami Iyer, page 7 of the filed PDF · View the filing
Management said the company has been producing 800-900 tonnes and filed for PLI incentive, with payment expected soon.
Answered by S. Subramanian
Asked by Damayanti Kerai: What is the status of PEN-G supplies and PLI benefits?
p. 6
“So, the PEN-G plant, we have been continuously achieving a capacity of around more than 800 tonnes to 900 tonnes is the range we have been producing.”
S. Subramanian, page 6 of the filed PDF · View the filing
Management described plans to transfer products into the facility and cited SGA and procurement synergies.
Answered by Swami Iyer
Asked by Neha Manpuria: How will Lannett's utilization be improved and what synergies are expected?
p. 9
“Lannett has a fair amount of unutilized capacity, which we think is a big plus, because we can use this capacity to bring in products in the US that we could not do earlier.”
Swami Iyer, page 9 of the filed PDF · View the filing
Management said US filings are imminent and detailed progress on European filings including Denosumab and Omalizumab.
Answered by Satakarni Makkapati
Asked by Bino: What is the update on the biosimilar Xolair filing in the US and other biosimilar pipeline progress?
p. 10
“So, the US filing this year is imminent. One quarter here and there, we expect the first filings to happen, and we are actively engaging with the agency.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
Management laid out a timeline where Unit 1 revenue begins around 2028 and Unit 2 around 2031.
Answered by Satakarni Makkapati
Asked by Bino: What revenue ramp-up can be expected from the Merck biologics manufacturing partnership in FY28/29?
p. 10
“So, in a nutshell, the structure for TheraNym is designed specifically to de-risk the CapEx ramp with contracted volumes from unit one, providing revenue visibility from 2028 onwards, before the full capital cycle of unit two completes and unit two will start generating revenues from 2031.”
Satakarni Makkapati, page 10 of the filed PDF · View the filing
Management said the acquisition accelerates entry into integrated CRDMO capabilities and saves years versus greenfield investment.
Answered by S. Subramanian
Asked by Shrikant Akolkar: What is the rationale for acquiring the A1 Biochem CRO business?
p. 12
“And we expedited the access to capabilities compared to the greenfield investment. If we take a greenfield investment to come to this level, I think to start up, it will take five years.”
S. Subramanian, page 12 of the filed PDF · View the filing
Management confirmed the Europe business achieved a 20% EBITDA margin, up from single digits a few years earlier.
Answered by S. Subramanian
Asked by Shyam Srinivasan: Has Europe EBITDA margin reached 20%?
p. 14
“Yeah, yeah, we have achieved the 20%.”
S. Subramanian, page 14 of the filed PDF · View the filing
Management explained the drop was due to completed Phase 3 studies and gave a full-year R&D range.
Answered by S. Subramanian
Asked by Kunal Dhamesha: What is the FY27 guidance for R&D expenses given the quarterly drop?
p. 15
“And this year it will be somewhere around Rs. 1,450 to 1,500, that's the maximum we have seen.”
S. Subramanian, page 15 of the filed PDF · View the filing
Management said no such payment has been received yet as of the June quarter.
Answered by Santanam Subramanian
Asked by Kunal Dhamesha: Has any upfront payment been received from STADA under the biosimilar agreement?
p. 17
“It has not been received, Kunal. As and when it is received, we will see the nature of the invoice, the nature of the agreement, etc. in consultation with the auditors we are doing.”
Santanam Subramanian, page 17 of the filed PDF · View the filing
Management said existing Lannett and Aurolife facilities give capacity to meet US demand if mandated, and cost economics would need to be a level playing field.
Answered by Swami Iyer
Asked by Tarang Agrawal: How is Aurobindo positioned for potential US onshoring requirements given unfavorable unit economics?
p. 16
“If somebody is prepared to handle it, Aurobindo is the one, because we already have a manufacturing facility in the form of Lannett, and that we can manufacture up to 350 million at ease, without too much of CAPEX.”
Swami Iyer, page 16 of the filed PDF · View the filing
Management projected combined Unit 1 and Unit 2 revenue of $150-200 million from 2032 with EBITDA margins of 35-50%.
Answered by Satakarni Makkapati
Asked by Jigar Valia: What revenue and margin scale should be expected from the CDMO business by 2028-2030?
p. 19
“So put together, Unit 1 and Unit 2, 2032, you should be looking at around US$150 to $200 million as a good case for the contract manufacturing business between Unit 1 and Unit 2.”
Satakarni Makkapati, page 19 of the filed PDF · View the filing
Risks flagged
Controlled substance production is capped by federal quota allocations, limiting growth potential
p. 7
“But controlled substance, you should be knowing that there is an overall limit on how much quota is available.”
Swami Iyer, page 7 of the filed PDF · View the filing
Eugia growth expected to slow to single digits due to lack of new approvals from unit three pending remediation
p. 14
“This year has been a steady growth, but it is not going to be double digit. It will be single digit because of lack of new approvals, both from unit, mainly from unit three.”
Yugandhar Puvvala, page 14 of the filed PDF · View the filing
US onshoring manufacturing requirements could raise costs without competitive advantage if pricing is not a level playing field
p. 18
“Today, if I do a product that's manufactured, imported from India and I manufacture in the US, I will be out of the market because in India, it will be a lot cheaper.”
Swami Iyer, page 18 of the filed PDF · View the filing
Geopolitical situation in the Middle East creates uncertainty for near-term EBITDA run-rate targets
p. 20
“But let us wait how the geopolitical situation in the Middle East is getting over.”
S. Subramanian, page 20 of the filed PDF · View the filing
Weak flu season in Europe during Q1 could affect antibiotic sales timing
p. 17
“Yeah, because Q1, you know, we have seen a very, you know, hot spell months over here.”
V. Muralidharan, page 17 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.